T41. SAFETY PROFILE OF ADJUNCTIVE PIMAVANSERIN IN THE ENHANCE STUDY, A PHASE 3 TRIAL FOR THE POTENTIAL TREATMENT OF SCHIZOPHRENIA IN PATIENTS WITH AN INADEQUATE RESPONSE TO ANTIPSYCHOTIC TREATMENT

BACKGROUND: Many patients with schizophrenia (SCZ) do not fully respond to antipsychotic (AP) treatment despite adherence and require augmentation, often with an AP with similar mode of action. Evidence supporting polypharmacy is limited and adding another AP increases associated risks of adverse ef...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Schizophr Bull
Main Authors: Bugarski-Kirola, Dragana, Nunez, Rene, Odetalla, Ramzey, Bari, Mohammed A, Bitter, Istvan, Feldman, Peter D, (Cathy) Liu, I-Yuan, Stankovic, Srdjan
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Poster Session III
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7234223/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/schbul/sbaa029.601
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados